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Background:  A novel and innovative transapical aortic valve implantation (TA-AVI) system received CE Mark approval in September 2011 and to 
date over 1000 commercial implants have been performed in Europe and South America. Following the success of the TA device, a FIM/CE approval 
trial of 80 patients treated with the company’s transfemoral aortic valve implantation (TF-AVI) system is currently performed. The first patient was 
implanted in May 2012 and the last study implant procedure took place in October 2013. The full 30 days primary endpoint results and mid-term 
safety outcomes of this study will be presented for the first time at ACC 2014.
Methods:  The trial is a single-arm study conducted at 5 centers in Brazil and Germany to treat 80 high-risk patients afflicted with severe aortic 
stenosis. Treated patients have a mean age of 83.7 ± 4.2 years, an STS Score of 7.6 ± 8.5, and a Logistic EuroSCORE of 27.6 ± 6.7. Baseline mean 
aortic gradient is 43.1 ± 17.7 mmHg and mean AVA is 0.7 ± 0.2 cm2. All patients presented in NYHA Class III/IV at screening and nearly 2/3 are 
female. All patients provided EC-approved written informed consent.
results:  Procedure success rate is 93.8% (n=75) with 3 valve-in-valve procedures and 2 failed implantations due to one instance of annular 
rupture and one case of bioprosthesis leaflet tear. Both failed procedures occurred during post-dilatation. The implant procedures were performed 
using small, medium and large valves covering an annular range of 21mm to 27mm. An ECHO analysis at 30 days reveals only 4 patients (5.4%) with 
moderate (Grade 2) paravalvular leak - there were no patients with a leak above Grade 2. The mean gradient is reduced to 7.9 ± 2.9 mmHg and the 
opening area is 1.8 ± 0.4 cm2. At 30 days there are 2 deaths, 2 strokes and no MI reported. Only 8 new pacemaker implantations were required by 
30 days for a rate of 10.0%. Mid-term safety results are available in March 2014.
conclusions:  These acute outcomes data confirm the safety and feasibility of use of this new 2nd Generation TF-AVI system. Market approval of 
the system is expected by January 2014 and the results at 6 months will be available at ACC in March 2014.
